A VISIONaerie® approach
We discover, develop and commercialize first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases
News Highlights
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial R... Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® ... Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the ...STOCK Quote
NASDAQ: AERI
$16.98USD
Feb 26, 10:11 AM ET
VOLUME
234,812
DAY LOW/HIGH
$15.76/$17.67
52 - WEEK LOW/HIGH
$9.01/$19.42
